These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25176167)

  • 61. Frontoparietal Activation During Response Inhibition Predicts Remission to Antidepressants in Patients With Major Depression.
    Gyurak A; Patenaude B; Korgaonkar MS; Grieve SM; Williams LM; Etkin A
    Biol Psychiatry; 2016 Feb; 79(4):274-81. PubMed ID: 25891220
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder.
    Shelton RC; Parikh SV; Law RA; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Macaluso M; Hain DT; Aguilar AL; Brown K; Lewis DJ; Jablonski MR; Greden JF
    Psychiatry Res; 2020 Aug; 290():113017. PubMed ID: 32485484
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Whole-genome expression analysis reveals genes associated with treatment response to escitalopram in major depression.
    Pettai K; Milani L; Tammiste A; Võsa U; Kolde R; Eller T; Nutt D; Metspalu A; Maron E
    Eur Neuropsychopharmacol; 2016 Sep; 26(9):1475-1483. PubMed ID: 27461515
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Faster onset of antidepressant effects of citalopram compared with sertraline in drug-naïve first-episode major depressive disorder in a Chinese population: a 6-week double-blind, randomized comparative study.
    Hsu JW; Su TP; Huang CY; Chen YS; Chou YH
    J Clin Psychopharmacol; 2011 Oct; 31(5):577-81. PubMed ID: 21869697
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study.
    Mrazek DA; Biernacka JM; McAlpine DE; Benitez J; Karpyak VM; Williams MD; Hall-Flavin DK; Netzel PJ; Passov V; Rohland BM; Shinozaki G; Hoberg AA; Snyder KA; Drews MS; Skime MK; Sagen JA; Schaid DJ; Weinshilboum R; Katzelnick DJ
    J Clin Psychopharmacol; 2014 Jun; 34(3):313-7. PubMed ID: 24743713
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Citalopram in Treatment of Pregnant Women With Panic Disorder: A Retrospective Study.
    Uguz F
    J Clin Psychopharmacol; 2020; 40(6):615-617. PubMed ID: 32991527
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: outcomes following randomized switch to either duloxetine or escitalopram.
    Raskin J; George T; Granger RE; Hussain N; Zhao GW; Marangell LB
    J Psychiatr Res; 2012 May; 46(5):667-74. PubMed ID: 22410206
    [TBL] [Abstract][Full Text] [Related]  

  • 68. An open-label trial of citalopram for major depression in patients with hepatitis C.
    Gleason OC; Yates WR; Isbell MD; Philipsen MA
    J Clin Psychiatry; 2002 Mar; 63(3):194-8. PubMed ID: 11926717
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE).
    Frasure-Smith N; Koszycki D; Swenson JR; Baker B; van Zyl LT; Laliberté MA; Abramson BL; Lambert J; Gravel G; Lespérance F
    Psychosom Med; 2006; 68(1):87-93. PubMed ID: 16449416
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy.
    Leo R; Di Lorenzo G; Tesauro M; Razzini C; Forleo GB; Chiricolo G; Cola C; Zanasi M; Troisi A; Siracusano A; Lauro R; Romeo F
    J Clin Psychiatry; 2006 Nov; 67(11):1760-6. PubMed ID: 17196057
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Initial Severity Effects on Residual Symptoms in Response and Remission: A STAR*D Study During and After Failed Citalopram Treatment.
    Madhoo M; Levine SZ
    J Clin Psychopharmacol; 2015 Aug; 35(4):450-3. PubMed ID: 26066336
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Lavender and dodder combined herbal syrup versus citalopram in major depressive disorder with anxious distress: A double-blind randomized trial.
    Firoozeei TS; Barekatain M; Karimi M; Zargaran A; Akhondzadeh S; Rezaeizadeh H
    J Integr Med; 2020 Sep; 18(5):409-415. PubMed ID: 32739466
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome.
    Tack J; Broekaert D; Fischler B; Van Oudenhove L; Gevers AM; Janssens J
    Gut; 2006 Aug; 55(8):1095-103. PubMed ID: 16401691
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Basal prolactin values correlate with response to reboxetine treatment in major depression, but not with response to citalopram.
    Moeller O; Hetzel G; Michael N; Rothermundt M; Arolt V; Erfurth A
    Neuropsychobiology; 2005; 51(2):67-71. PubMed ID: 15741746
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
    Bobo WV; Chen H; Trivedi MH; Stewart JW; Nierenberg AA; Fava M; Kurian BT; Warden D; Morris DW; Luther JF; Husain MM; Cook IA; Lesser IM; Kornstein SG; Wisniewski SR; Rush AJ; Shelton RC
    J Affect Disord; 2011 Oct; 133(3):467-76. PubMed ID: 21601287
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study.
    Ou JJ; Xun GL; Wu RR; Li LH; Fang MS; Zhang HG; Xie SP; Shi JG; Du B; Yuan XQ; Zhao JP
    Psychopharmacology (Berl); 2011 Feb; 213(2-3):639-46. PubMed ID: 20340011
    [TBL] [Abstract][Full Text] [Related]  

  • 77. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?
    Bandelow B; Baldwin DS; Dolberg OT; Andersen HF; Stein DJ
    J Clin Psychiatry; 2006 Sep; 67(9):1428-34. PubMed ID: 17017830
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.
    McGrath PJ; Khan AY; Trivedi MH; Stewart JW; Morris DW; Wisniewski SR; Miyahara S; Nierenberg AA; Fava M; Rush AJ
    J Clin Psychiatry; 2008 Dec; 69(12):1847-55. PubMed ID: 19026268
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
    Hjalmarsson L; Corcos M; Jeammet P
    Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression.
    Zhdanov A; Atluri S; Wong W; Vaghei Y; Daskalakis ZJ; Blumberger DM; Frey BN; Giacobbe P; Lam RW; Milev R; Mueller DJ; Turecki G; Parikh SV; Rotzinger S; Soares CN; Brenner CA; Vila-Rodriguez F; McAndrews MP; Kleffner K; Alonso-Prieto E; Arnott SR; Foster JA; Strother SC; Uher R; Kennedy SH; Farzan F
    JAMA Netw Open; 2020 Jan; 3(1):e1918377. PubMed ID: 31899530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.